## James C Grotta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4151829/publications.pdf

Version: 2024-02-01

430 papers 36,263 citations

100 h-index 3915

g-index

441 all docs

441 docs citations

times ranked

441

20718 citing authors

#	Article	IF	CITATIONS
1	A randomized controlled trial to optimize patient's selection for endovascular treatment in acute ischemic stroke (SELECT2): Study protocol. International Journal of Stroke, 2022, 17, 689-693.	5.9	33
2	Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial. International Journal of Stroke, 2022, 17, 806-809.	5.9	21
3	Stroke Systems of Care and Impact on Acute Stroke Treatment. , 2022, , 725-734.e4.		O
4	Pharmacologic Modification of Acute Cerebral Ischemia. , 2022, , 831-851.e6.		0
5	Neurology Trainee Attitudes Toward Neurointervention: Results From an International Survey. , 2022, 2, .		2
6	Mobile Stroke Units: Current Evidence and Impact. Current Neurology and Neuroscience Reports, 2022, 22, 71-81.	4.2	7
7	Comparison of Mobile Stroke Unit With Usual Care for Acute Ischemic Stroke Management. JAMA Neurology, 2022, 79, 281.	9.0	33
8	Targeting Hemoglobin to Reduce Delayed Cerebral Ischemia After Subarachnoid Hemorrhage. Translational Stroke Research, 2022, 13, 725-735.	4.2	11
9	Immediate Recanalization of Largeâ€Vessel Occlusions by Tissue Plasminogen Activator Occurs in 28% of Patients Treated in a Mobile Stroke Unit. , 2022, 2, .		3
10	Mobile Stroke Units: Evidence, Gaps, and Next Steps. Stroke, 2022, 53, 2103-2113.	2.0	25
11	Prophylactic Therapies for Morbidity and Mortality After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis of Randomized Trials. Stroke, 2022, 53, 1993-2005.	2.0	23
12	Hemorrhage Enlargement Is More Frequent in the First 2 Hours: A Prehospital Mobile Stroke Unit Study. Stroke, 2022, 53, 2352-2360.	2.0	11
13	How Frequent is the One-Hour tPA Infusion Interrupted or Delayed?. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106471.	1.6	3
14	Machine Learning Automated Detection of Large Vessel Occlusion From Mobile Stroke Unit Computed Tomography Angiography. Stroke, 2022, 53, 1651-1656.	2.0	16
15	Aneurysmal subarachnoid haemorrhageâ€"cerebral vasospasm and prophylactic ibuprofen: a randomised controlled pilot trial protocol. BMJ Open, 2022, 12, e058895.	1.9	1
16	Thromboelastography Indices for Predicting Outcomes After Aneurysmal Subarachnoid Hemorrhage: A Prospective Study. Stroke, 2022, 53, 101161STROKEAHA122039372.	2.0	3
17	Mobile Stroke Unit Operational Metrics: Institutional Experience, Systematic Review and Meta-Analysis. Frontiers in Neurology, 2022, 13, .	2.4	1
18	Thrombectomy versus Medical Management in Mild Strokes due to Large Vessel Occlusion: Exploratory Analysis from the EXTENDâ€A Trials and a Pooled International Cohort. Annals of Neurology, 2022, 92, 364-378.	5.3	14

#	Article	IF	CITATIONS
19	Risk of intracranial hemorrhage associated with pregnancy in women with cerebral arteriovenous malformations. Journal of NeuroInterventional Surgery, 2021, 13, 707-710.	3.3	14
20	Endovascular thrombectomy in patients with large core ischemic stroke: a cost-effectiveness analysis from the SELECT study. Journal of NeuroInterventional Surgery, 2021, 13, 875-882.	3.3	20
21	The multiarm optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: Rationale and methods. International Journal of Stroke, 2021, 16, 873-880.	5.9	24
22	Characteristics of Acute Stroke Patients Readmitted to Inpatient Rehabilitation Facilities: A Cohort Study. PM and R, 2021, 13, 479-487.	1.6	4
23	Early Infarct Growth Rate Correlation With Endovascular Thrombectomy Clinical Outcomes. Stroke, 2021, 52, 57-69.	2.0	49
24	National Institutes of Health Stroke Scale as an Outcome Measure for Acute Stroke Trials. Stroke, 2021, 52, 142-143.	2.0	11
25	Mobile Stroke Units: Current and Future Impact on Stroke Care. Seminars in Neurology, 2021, 41, 009-015.	1.4	7
26	Improving Stroke Treatment and Outcomes With Mobile Stroke Units. JAMA - Journal of the American Medical Association, 2021, 325, 441.	7.4	8
27	Education Research: Challenges Faced by Neurology Trainees in a Neuro-Intervention Career Track. Neurology, 2021, 96, e2028-e2032.	1.1	8
28	Longitudinal Neuroimaging Evaluation of the Corticospinal Tract in Patients with Stroke Treated with Autologous Bone Marrow Cells. Stem Cells Translational Medicine, 2021, 10, 943-955.	3.3	5
29	Integrated Stroke System Model Expands Availability of Endovascular Therapy While Maintaining Quality Outcomes. Stroke, 2021, 52, 1022-1029.	2.0	7
30	Clinical and Neuroimaging Outcomes of Direct Thrombectomy vs Bridging Therapy in Large Vessel Occlusion. Neurology, 2021, 96, e2839-e2853.	1.1	11
31	Utilization and Availability of Advanced Imaging in Patients With Acute Ischemic Stroke. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006989.	2.2	39
32	Non-contrast head CT-based thrombolysis for wake-up/unknown onset stroke is safe: A single-center study and meta-analysis. International Journal of Stroke, 2021, , 174749302110063.	5.9	1
33	Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease. Seminars in Neurology, 2021, 41, 365-387.	1.4	2
34	SELECTion criteria for large core trials: dogma or data?. Journal of NeuroInterventional Surgery, 2021, 13, 500-504.	3.3	17
35	Impact of mobile stroke units. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 815-822.	1.9	29
36	The Story of Intracerebral Hemorrhage. Stroke, 2021, 52, 1905-1914.	2.0	34

#	Article	IF	Citations
37	Complexities of Reperfusion Therapy in Patients With Ischemic Stroke Pretreated With Direct Oral Anticoagulants. JAMA Neurology, 2021, 78, 517.	9.0	3
38	Hematoma Enlargement as a Target for Treating Intracerebral Hemorrhage. Neurology, 2021, 97, 355-356.	1.1	1
39	Dosing Tissue Plasminogen Activator on a Mobile Stroke Unit: Comparison Between Estimated and Hospital-Measured Weights. Journal of Neuroscience Nursing, 2021, 53, 166-169.	1.1	O
40	Association Between 2010 Medicare Reform and Inpatient Rehabilitation Access in People With Intracerebral Hemorrhage. Journal of the American Heart Association, 2021, 10, e020528.	3.7	5
41	Leveraging Multimedia Patient Engagement to Address Minority Cerebrovascular Health Needs: Prospective Observational Study. Journal of Medical Internet Research, 2021, 23, e28748.	4.3	1
42	Sonothrombolysis in Patients With Acute Ischemic Stroke With Large Vessel Occlusion: An Individual Patient Data Meta-Analysis. Stroke, 2021, 52, 3786-3795.	2.0	9
43	Direct to Angiography vs Repeated Imaging Approaches in Transferred Patients Undergoing Endovascular Thrombectomy. JAMA Neurology, 2021, 78, 916.	9.0	33
44	Retrospectively Collected EQ-5D-5L Data as Valid Proxies for Imputing Missing Information in Longitudinal Studies. Value in Health, 2021, 24, 1720-1727.	0.3	6
45	Standardized Nomenclature for Modified Rankin Scale Global Disability Outcomes: Consensus Recommendations From Stroke Therapy Academic Industry Roundtable XI. Stroke, 2021, 52, 3054-3062.	2.0	74
46	Prospective, Multicenter, Controlled Trial of Mobile Stroke Units. New England Journal of Medicine, 2021, 385, 971-981.	27.0	128
47	Successful conduct of an acute stroke clinical trial during COVID. PLoS ONE, 2021, 16, e0243603.	2.5	5
48	Blood pressure excursions in acute ischemic stroke patients treated with intravenous thrombolysis. Journal of Hypertension, 2021, 39, 266-272.	0.5	10
49	Fifty Years of Acute Ischemic Stroke Treatment: A Personal History. Cerebrovascular Diseases, 2021, 50, 666-680.	1.7	13
50	Dual Antiplatelet Therapy Is Associated With Coagulopathy Detectable by Thrombelastography in Acute Stroke. Journal of Intensive Care Medicine, 2020, 35, 68-73.	2.8	19
51	Optimizing Patient Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT): A Prospective, Multicenter Cohort Study of Imaging Selection. Annals of Neurology, 2020, 87, 419-433.	5.3	52
52	Emergency Medicine Physicians Accurately Select Acute Stroke Patients for Tissue-Type Plasminogen Activator Treatment Using a Checklist. Stroke, 2020, 51, 663-665.	2.0	6
53	Retrospective collection of 90-day modified Rankin Scale is accurate. Clinical Trials, 2020, 17, 637-643.	1.6	12
54	Pulse pressure variability is associated with unfavorable outcomes in acute ischaemic stroke patients treated with intravenous thrombolysis. European Journal of Neurology, 2020, 27, 2453-2462.	3.3	8

#	Article	IF	CITATIONS
55	National Institutes of Health StrokeNet During the Time of COVID-19 and Beyond. Stroke, 2020, 51, 2580-2586.	2.0	13
56	Impact of Initial Imaging Protocol on Likelihood of Endovascular Stroke Therapy. Stroke, 2020, 51, 3055-3063.	2.0	28
57	Lone Star Stroke Consortium. Stroke, 2020, 51, 3778-3786.	2.0	3
58	Early Lessons From World War COVID Reinventing Our Stroke Systems of Care. Stroke, 2020, 51, 2268-2272.	2.0	14
59	Evolving Role of Mobile Stroke Units Within the Prehospital Stroke Systems of Care. Stroke, 2020, 51, 1637-1638.	2.0	3
60	Triage imaging and outcome measures for large core stroke thrombectomy $\hat{a} \in \hat{a}$ a systematic review and meta-analysis. Journal of NeuroInterventional Surgery, 2020, 12, neurintsurg-2019-015509.	3.3	21
61	Prehospital stroke management in the thrombectomy era. Lancet Neurology, The, 2020, 19, 601-610.	10.2	47
62	Coagulation Differences Detectable in Deep and Lobar Primary Intracerebral Hemorrhage Using Thromboelastography. Neurosurgery, 2020, 87, 918-924.	1.1	12
63	Redefined Measure of Early Neurological Improvement Shows Treatment Benefit of Alteplase Over Placebo. Stroke, 2020, 51, 1226-1230.	2.0	31
64	Endovascular Thrombectomy for Acute Ischemic Strokes. Stroke, 2020, 51, 1207-1217.	2.0	55
65	Safety and efficacy of dual antiplatelet pretreatment in patients with ischemic stroke treated with IV thrombolysis. Neurology, 2020, 94, e657-e666.	1.1	25
66	Mobile Stroke Unit Computed Tomography Angiography Substantially Shortens Door-to-Puncture Time. Stroke, 2020, 51, 1613-1615.	2.0	40
67	Enhanced dispatch and rendezvous doubles the catchment area and number of patients treated on a mobile stroke unit. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104894.	1.6	9
68	Use of a Smartphone-Based Mobile App for Weight Management in Obese Minority Stroke Survivors: Pilot Randomized Controlled Trial With Open Blinded End Point. JMIR MHealth and UHealth, 2020, 8, e17816.	3.7	23
69	Stroke in Critically Ill Cancer Patients. , 2020, , 367-379.		0
70	Response by Sarraj et al to Letter Regarding Article, "Endovascular Thrombectomy for Acute Ischemic Strokes: Current US Access Paradigms and Optimization Methodology― Stroke, 2020, 51, e175-e176.	2.0	0
71	Outcomes of Endovascular Thrombectomy vs Medical Management Alone in Patients With Large Ischemic Cores. JAMA Neurology, 2019, 76, 1147.	9.0	118
72	Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial. Stem Cells, 2019, 37, 1481-1491.	3.2	35

#	Article	IF	CITATIONS
73	Idarucizumab for Reversal of Dabigatran in Early/Emergency Surgeries: A Case Series. Journal of Emergency Medicine, 2019, 57, e167-e173.	0.7	O
74	Intravenous Thrombolysis., 2019,, 58-79.		0
75	Neurological Deterioration in Acute Ischemic Stroke. , 2019, , 101-118.		0
76	Organization of Stroke Care., 2019,, 215-225.		0
77	Ischemic Stroke Etiology and Secondary Prevention. , 2019, , 119-152.		0
78	Association Between Intravenous Thrombolysis and Anaphylaxis Among Medicare Beneficiaries With Acute Ischemic Stroke. Stroke, 2019, 50, 3283-3285.	2.0	3
79	Machine Learning–Enabled Automated Determination of Acute Ischemic Core From Computed Tomography Angiography. Stroke, 2019, 50, 3093-3100.	2.0	71
80	Stroke in Critically III Cancer Patients. , 2019, , 1-13.		0
81	Emergency Department Door-to-Puncture Time Since 2014. Stroke, 2019, 50, 1774-1780.	2.0	24
82	Stroke Treatment Academic Industry Roundtable X. Stroke, 2019, 50, 1026-1031.	2.0	120
83	Acute dual antiplatelet therapy for minor ischaemic stroke or transient ischaemic attack. BMJ: British Medical Journal, 2019, 364, l895.	2.3	21
84	Interhospital Transfer of Stroke Patients for Endovascular Treatment. Circulation, 2019, 139, 1578-1580.	1.6	9
85	Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Neurology, The, 2019, 18, 338-347.	10.2	61
86	14th International Symposium on Thrombolysis, Thrombectomy and Acute Stroke Therapy: Proceedings and summary of discussions. International Journal of Stroke, 2019, 14, 439-441.	5.9	6
87	Real-World Treatment Trends in Endovascular Stroke Therapy. Stroke, 2019, 50, 683-689.	2.0	80
88	Direct Assessment of Health Utilities Using the Standard Gamble Among Patients With Primary Intracerebral Hemorrhage. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005606.	2.2	8
89	Stroke in the elderly. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 393-418.	1.8	27
90	Intraosseous Administration of Tissue Plasminogen Activator on a Mobile Stroke Unit. Prehospital Emergency Care, 2019, 23, 447-452.	1.8	2

#	Article	IF	Citations
91	Cocaine Use is Associated with More Rapid Clot Formation and Weaker Clot Strength in Acute Stroke Patients. , $2019, 2, .$		2
92	Thrombelastography Suggests Hypercoagulability in Patients with Renal Dysfunction and Intracerebral Hemorrhage. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 1350-1356.	1.6	14
93	HeadPoST. Neurology, 2018, 90, 885-889.	1.1	18
94	Transatlantic Differences in Management of Carotid Stenosis: BRIDGing the Gap in StrokE Management (BRIDGE) Project. Neurohospitalist, The, 2018, 8, 113-123.	0.8	2
95	Delivery of xenon-containing echogenic liposomes inhibits early brain injury following subarachnoid hemorrhage. Scientific Reports, 2018, 8, 450.	3.3	36
96	Time to Decision and Treatment With tPA (Tissue-Type Plasminogen Activator) Using Telemedicine Versus an Onboard Neurologist on a Mobile Stroke Unit. Stroke, 2018, 49, 1528-1530.	2.0	23
97	Benefits of stroke treatment delivered using a mobile stroke unit trial. International Journal of Stroke, 2018, 13, 321-327.	5.9	50
98	Safety and Feasibility of Argatroban, Recombinant Tissue Plasminogen Activator, and Intra-Arterial Therapy in Stroke (ARTSS-IA Study). Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 3647-3651.	1.6	22
99	STAIR X. Stroke, 2018, 49, 2241-2247.	2.0	26
100	Endovascular Thrombectomy for Mild Strokes: How Low Should We Go?. Stroke, 2018, 49, 2398-2405.	2.0	100
101	Antiplatelet Therapy after Ischemic Stroke or TIA. New England Journal of Medicine, 2018, 379, 291-292.	27.0	19
102	Unique Contribution of Haptoglobin and Haptoglobin Genotype in Aneurysmal Subarachnoid Hemorrhage. Frontiers in Physiology, 2018, 9, 592.	2.8	28
103	To Treat or Not to Treat?. Stroke, 2018, 49, 1933-1938.	2.0	11
104	Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. Lancet Neurology, The, 2018, 17, 885-894.	10.2	229
105	Abstract WMP87: Comparison of Patient-centered Quality of Life Utilities Using 3 Different Methods Across Modified Rankin Scale Scores - Experience From the ARTSS-2 Trial (Randomized, Multi-center) Tj ETQq1 3	1 0.784314 2.0	rgBT /Over
106	Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials. International Journal of Stroke, 2018, 13, 175-189.	5.9	36
107	Telemedicine Can Replace the Neurologist on a Mobile Stroke Unit. Stroke, 2017, 48, 493-496.	2.0	63
108	Small vessel disease and clinical outcomes after IV rt-PA treatment. Acta Neurologica Scandinavica, 2017, 136, 72-77.	2.1	61

#	Article	IF	CITATIONS
109	Mobile stroke units for prehospital thrombolysis, triage, and beyond: benefits and challenges. Lancet Neurology, The, 2017, 16, 227-237.	10.2	164
110	Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen) Tj ETQq0 0 0 rgBT	/Qverlock	10 Tf 50 70
111	â€~Last known well' alone should not determine triage for patients with stroke and symptoms of large vessel occlusion. Journal of NeuroInterventional Surgery, 2017, 9, 334-335.	3.3	2
112	Telemedicine-guided education on secondary stroke and fall prevention following inpatient rehabilitation for Texas patients with stroke and their caregivers: a feasibility pilot study. BMJ Open, 2017, 7, e017340.	1.9	19
113	The PRE-hospital Stroke Treatment Organization. International Journal of Stroke, 2017, 12, 932-940.	5.9	54
114	Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal. Current Neurology and Neuroscience Reports, 2017, 17, 67.	4.2	5
115	Response by Barreto and Grotta to Letter Regarding Article, "Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)― Stroke, 2017, 48, e259.	2.0	O
116	Rethinking Training and Distribution of Vascular Neurology Interventionists in the Era of Thrombectomy. Stroke, 2017, 48, 2313-2317.	2.0	25
117	Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population. Circulation, 2017, 135, 128-139.	1.6	129
118	Agreement Among Stroke Faculty and Fellows in Treating Ischemic Stroke Patients With Tissue-Type Plasminogen Activator and Thrombectomy. Stroke, 2017, 48, 222-224.	2.0	16
119	Bringing Emergency Neurology to Ambulances: Mobile Stroke Unit. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 713-717.	2.1	12
120	Radiation Monitoring Results from the First Year of Operation of a Unique Ambulance-based Computed Tomography Unit for the Improved Diagnosis and Treatment of Stroke Patients. Health Physics, 2016, 110, S73-S80.	0.5	11
121	Prospective, open″abel safety study of intravenous recombinant tissue plasminogen activator in wakeâ€up stroke. Annals of Neurology, 2016, 80, 211-218.	5.3	36
122	Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998–2011. International Journal of Stroke, 2016, 11, 198-205.	5.9	1
123	Swipe out Stroke: Feasibility and efficacy of using a smart-phone based mobile application to improve compliance with weight loss in obese minority stroke patients and their carers. International Journal of Stroke, 2016, 11, 593-603.	5.9	19
124	Acute Stroke Imaging Research Roadmap III Imaging Selection and Outcomes in Acute Stroke Reperfusion Clinical Trials. Stroke, 2016, 47, 1389-1398.	2.0	88
125	Higher prehospital blood pressure prolongs door to needle thrombolysis times: a target for quality improvement?. American Journal of Emergency Medicine, 2016, 34, 1268-1272.	1.6	2
126	Impact of heart rate on admission on mortality and morbidity in acute ischaemic stroke patients – results from VISTA. European Journal of Neurology, 2016, 23, 1750-1756.	3.3	23

#	Article	IF	Citations
127	Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes. Stroke, 2016, 47, 2373-2379.	2.0	193
128	Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2). Stroke, 2016, 47, 2888-2895.	2.0	131
129	Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke. Stroke, 2016, 47, 2880-2887.	2.0	48
130	Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurology, The, 2016, 15, 925-933.	10.2	187
131	Pharmacologic Modification of Acute Cerebral Ischemia. , 2016, , 916-936.e5.		0
132	Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke. Stroke, 2016, 47, 581-641.	2.0	539
133	Quantification of Cerebral Edema After Subarachnoid Hemorrhage. Neurocritical Care, 2016, 25, 64-70.	2.4	26
134	Thrombelastography does not predict clinical response to rtPA for acute ischemic stroke. Journal of Thrombosis and Thrombolysis, 2016, 41, 505-510.	2.1	26
135	The effects of telemedicine on racial and ethnic disparities in access to acute stroke care. Journal of Telemedicine and Telecare, 2016, 22, 114-120.	2.7	39
136	Sex Disparities in Access to Acute Stroke Care: Can Telemedicine Mitigate this Effect?. Journal of Health Disparities Research and Practice, $2016, 9, .$	1.1	2
137	Telemedicineâ€guided remote enrollment of patients into an acute stroke trial. Annals of Clinical and Translational Neurology, 2015, 2, 38-42.	3.7	14
138	Patient Refusal of Thrombolytic Therapy for Suspected Acute Ischemic Stroke. International Journal of Stroke, 2015, 10, 882-886.	5.9	13
139	Posterior Circulation Stroke is Associated with Prolonged Door-to-Needle Time. International Journal of Stroke, 2015, 10, 672-678.	5.9	81
140	The Effect of Telemedicine on Access to Acute Stroke Care in Texas: The Story of Age Inequalities. Stroke Research and Treatment, 2015, 2015, 1-6.	0.8	6
141	Is the ICH score a valid predictor of mortality in intracerebral hemorrhage?. Journal of the American Association of Nurse Practitioners, 2015, 27, 351-355.	0.9	17
142	Seeking best medical treatment for hyperacute intracerebral hemorrhage. Neurology, 2015, 84, 444-445.	1.1	3
143	Safety and efficacy of desmoteplase given 3–9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurology, The, 2015, 14, 575-584.	10.2	95
144	Implementing a Mobile Stroke Unit Program in the United States. JAMA Neurology, 2015, 72, 229.	9.0	60

#	Article	IF	Citations
145	Stroke Neurologist's Perspective on the New Endovascular Trials. Stroke, 2015, 46, 1447-1452.	2.0	116
146	Decompressive hemicraniectomy with or without clot evacuation for large spontaneous supratentorial intracerebral hemorrhages. Clinical Neurology and Neurosurgery, 2015, 128, 117-122.	1.4	34
147	Adopting a Patient-Centered Approach to Primary Outcome Analysis of Acute Stroke Trials Using a Utility-Weighted Modified Rankin Scale. Stroke, 2015, 46, 2238-2243.	2.0	139
148	Associations of chronic heart failure with outcome in acute ischaemic stroke patients who received systemic thrombolysis: analysis from VISTA. European Journal of Neurology, 2015, 22, 163-169.	3.3	20
149	Selection for Delayed Intravenous Alteplase Treatment Based on a Prognostic Score. International Journal of Stroke, 2015, 10, 90-94.	5.9	8
150	Methodological issues for designing and conducting a multicenter, international clinical trial in Acute Stroke: Experience from ARTSS-2 trial. Contemporary Clinical Trials, 2015, 44, 139-148.	1.8	5
151	Establishing the First Mobile Stroke Unit in the United States. Stroke, 2015, 46, 1384-1391.	2.0	97
152	Benefits of Stroke Treatment Using a Mobile Stroke Unit Compared With Standard Management. Stroke, 2015, 46, 3370-3374.	2.0	106
153	National Institutes of Health Stroke Scale Item Profiles as Predictor of Patient Outcome. Stroke, 2015, 46, 395-400.	2.0	30
154	Intravenous thrombolysis or endovascular therapy for acute ischemic stroke associated with cervical internal carotid artery occlusion: the ICARO-3 study. Journal of Neurology, 2015, 262, 459-468.	3.6	43
155	Thromboelastography in Patients with Acute Ischemic Stroke. International Journal of Stroke, 2015, 10, 194-201.	5.9	48
156	Combination of Thrombolytic Therapy with Antithrombotics and Neuroprotectants., 2015,, 65-80.		0
157	Mobile Stroke Unit Hits the Road in Houston. US Neurology, 2015, 11, 59.	0.2	0
158	Acute Intravenous Tissue Plasminogen Activator Therapy does not Impact Community Discharge after Inpatient Rehabilitation. International Journal of Neurorehabilitation, 2015, 2, .	0.1	4
159	Clot Strength as Measured by Thrombelastography Correlates with Platelet Reactivity in Stroke Patients. Annals of Clinical and Laboratory Science, 2015, 45, 301-7.	0.2	6
160	Comparison Between a Standardized Questionnaire and Expert Clinicians for Capacity Assessment in Stroke Clinical Trials. Stroke, 2014, 45, e229-32.	2.0	5
161	Neurofluctuation in patients with subcortical ischemic stroke. Neurology, 2014, 83, 398-405.	1.1	33
162	lodinated Contrast Does Not Alter Clotting Dynamics in Acute Ischemic Stroke as Measured by Thromboelastography. Stroke, 2014, 45, 462-466.	2.0	11

#	Article	IF	CITATIONS
163	<i>RNF213</i> Rare Variants in an Ethnically Diverse Population With Moyamoya Disease. Stroke, 2014, 45, 3200-3207.	2.0	129
164	Endovascular Therapeutic Hypothermia for Acute Ischemic Stroke: ICTuS 2/3 Protocol. International Journal of Stroke, 2014, 9, 117-125.	5.9	70
165	Influence of Racial Differences on Outcomes after Thrombolytic Therapy in Acute Ischemic Stroke. International Journal of Stroke, 2014, 9, 613-617.	5.9	7
166	tPA for Stroke. JAMA - Journal of the American Medical Association, 2014, 311, 1615.	7.4	29
167	Thrombelastography Detects the Anticoagulant Effect of Rivaroxaban in Patients With Stroke. Stroke, 2014, 45, 880-883.	2.0	28
168	Thrombelastography Detects Possible Coagulation Disturbance in Patients With Intracerebral Hemorrhage With Hematoma Enlargement. Stroke, 2014, 45, 683-688.	2.0	58
169	Prehospital Utility of Rapid Stroke Evaluation Using In-Ambulance Telemedicine. Stroke, 2014, 45, 2342-2347.	2.0	64
170	Validity of Acute Stroke Lesion Volume Estimation by Diffusion-Weighted Imaging–Alberta Stroke Program Early Computed Tomographic Score Depends on Lesion Location in 496 Patients With Middle Cerebral Artery Stroke. Stroke, 2014, 45, 3583-3588.	2.0	36
171	Stroke: new horizons in treatment. Lancet Neurology, The, 2014, 13, 2-3.	10.2	10
172	Racial and Gender Differences in Stroke Severity, Outcomes, and Treatment in Patients with Acute Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, e255-e261.	1.6	87
173	Intravenous Fibrinolysis Eligibility: A Survey of Stroke Clinicians' Practice Patterns and Review of the Literature. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 2130-2138.	1.6	15
174	Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet, The, 2014, 384, 1929-1935.	13.7	1,971
175	Emergence of the Primary Pediatric Stroke Center. Stroke, 2014, 45, 2018-2023.	2.0	108
176	CTP infarct core may predict poor outcome in stroke patients treated with IV t-PA. Journal of the Neurological Sciences, 2014, 340, 165-169.	0.6	5
177	Pretreatment Blood–Brain Barrier Damage and Post-Treatment Intracranial Hemorrhage in Patients Receiving Intravenous Tissue-Type Plasminogen Activator. Stroke, 2014, 45, 2030-2035.	2.0	73
178	Acute Antithrombotic Treatment of Ischemic Stroke. Current Vascular Pharmacology, 2014, 12, 353-364.	1.7	8
179	Design of a Prospective, Dose-Escalation Study Evaluating the Safety of Pioglitazone for Hematoma Resolution in Intracerebral Hemorrhage (SHRINC). International Journal of Stroke, 2013, 8, 388-396.	5.9	65
180	Streamlining of prehospital stroke management: the golden hour. Lancet Neurology, The, 2013, 12, 585-596.	10.2	229

#	Article	IF	CITATIONS
181	The University of Texas Houston Stroke Registry (UTHSR): implementation of enhanced data quality assurance procedures improves data quality. BMC Neurology, 2013, 13, 61.	1.8	22
182	Thrombolysis in Stroke Despite Contraindications or Warnings?. Stroke, 2013, 44, 727-733.	2.0	102
183	Hospitalâ€Acquired Symptomatic Urinary Tract Infection in Patients Admitted to an Academic Stroke Center Affects Discharge Disposition. PM and R, 2013, 5, 9-15.	1.6	15
184	Carotid Stenosis. New England Journal of Medicine, 2013, 369, 1143-1150.	27.0	82
185	Changes in Spleen Size in Patients with Acute Ischemic Stroke: A Pilot Observational Study. International Journal of Stroke, 2013, 8, 60-67.	5.9	72
186	Hypothermia for acute ischaemic stroke. Lancet Neurology, The, 2013, 12, 275-284.	10.2	167
187	Therapeutic Time Window and Dose Dependence of Xenon Delivered via Echogenic Liposomes for Neuroprotection in Stroke. CNS Neuroscience and Therapeutics, 2013, 19, 773-784.	3.9	52
188	Changing Demographics at a Comprehensive Stroke Center Amidst the Rise in Primary Stroke Centers. Stroke, 2013, 44, 1117-1123.	2.0	7
189	Stroke Severity as Well as Time Should Determine Stroke Patient Triage. Stroke, 2013, 44, 555-557.	2.0	19
190	Stroke Progress Review Group. Stroke, 2013, 44, S111-3.	2.0	6
191	The NINDS Stroke Progress Review Group Final Analysis and Recommendations. Stroke, 2013, 44, 2343-2350.	2.0	13
192	Defining Intravenous Recombinant Tissue Plasminogen Activator Failure. Stroke, 2013, 44, 819-821.	2.0	5
193	Review, Historical Context, and Clarifications of the NINDS rt-PA Stroke Trials Exclusion Criteria. Stroke, 2013, 44, 2500-2505.	2.0	65
194	Optimizing Prediction Scores for Poor Outcome After Intra-Arterial Therapy in Anterior Circulation Acute Ischemic Stroke. Stroke, 2013, 44, 3324-3330.	2.0	86
195	Adjunctive Medical Therapies for Acute Stroke Thrombolysis. Stroke, 2013, 44, 2377-2379.	2.0	1
196	CLOTBUST-Hands Free. Stroke, 2013, 44, 1641-1646.	2.0	29
197	Carotid Stenosis. New England Journal of Medicine, 2013, 369, 2359-2361.	27.0	8
198	Acute Stroke Imaging Research Roadmap II. Stroke, 2013, 44, 2628-2639.	2.0	192

#	Article	IF	CITATIONS
199	Details of a Prospective Protocol for a Collaborative Meta-Analysis of Individual Participant Data from all Randomized Trials of Intravenous rt-PA vs. Control: Statistical Analysis Plan for the Stroke Thrombolysis Trialists' Collaborative Meta-Analysis. International Journal of Stroke, 2013, 8, 278-283.	5.9	22
200	CLOTBUST-Hands Free. Stroke, 2013, 44, 3376-3381.	2.0	41
201	The NIHSS Score and its Components can Predict Cortical Stroke. , 2013, 2, 1026.		6
202	Abstract WP148: The BRIDGE Project ( <i>BRIDG</i> ing the gap in strok <i>E</i> ) Tj ETQq0 0 0 rgBT /Overlock 1	10 Tf 50 62 2.0	22 Td (manag
203	Frank Michio Yatsu, MD (1932–2012). Neurology, 2012, 78, 1907-1908.	1.1	0
204	The Argatroban and Tissue-Type Plasminogen Activator Stroke Study. Stroke, 2012, 43, 770-775.	2.0	93
205	Intracranial Atherosclerosis Is Associated with Progression of Neurological Deficit in Subcortical Stroke. Cerebrovascular Diseases, 2012, 33, 64-68.	1.7	22
206	Systemic Thrombolysis in Patients With Acute Ischemic Stroke and Internal Carotid ARtery Occlusion. Stroke, 2012, 43, 125-130.	2.0	86
207	Frank Michio Yatsu, MD. Stroke, 2012, 43, 1193-1194.	2.0	0
208	The Interaction of Aspiration Pneumonia with Demographic and Cerebrovascular Disease Risk Factors is Predictive of Discharge Level of Care in the Acute Stroke Patient. American Journal of Physical Medicine and Rehabilitation, 2012, 91, 141-147.	1.4	18
209	Timing of thrombolysis for acute ischemic stroke: "timing is everything―or "everyone is different― Annals of the New York Academy of Sciences, 2012, 1268, 141-144.	3.8	14
210	Inflammatory response to intraventricular hemorrhage: Time course, magnitude and effect of t-PA. Journal of the Neurological Sciences, 2012, 315, 93-95.	0.6	34
211	Nitric Oxide Facilitates Delivery and Mediates Improved Outcome of Autologous Bone Marrow Mononuclear Cells in a Rodent Stroke Model. PLoS ONE, 2012, 7, e32793.	2.5	9
212	Selecting stroke patients for intra-arterial therapy. Neurology, 2012, 78, 755-761.	1.1	17
213	Proteasome Inhibitor Reduces Astrocytic iNOS Expression and Functional Deficit after Experimental Intracerebral Hemorrhage in Rats. Translational Stroke Research, 2012, 3, 146-153.	4.2	12
214	Determinants of Effective Cooling During Endovascular Hypothermia. Neurocritical Care, 2012, 16, 413-420.	2.4	27
215	Reprint: Frank M. Yatsu, M.D International Journal of Stroke, 2012, 7, 369-370.	5.9	0
216	Is the Drip-and-Ship Approach to Delivering Thrombolysis for Acute Ischemic Stroke Safe?. Journal of Emergency Medicine, 2011, 41, 135-141.	0.7	42

#	Article	IF	CITATIONS
217	Pharmacologic Modification of Acute Cerebral Ischemia. , 2011, , 1049-1083.		1
218	IL-10 directly protects cortical neurons by activating Pl-3 kinase and STAT-3 pathways. Brain Research, 2011, 1373, 189-194.	2.2	127
219	Introduction. Neurotherapeutics, 2011, 8, 317-318.	4.4	0
220	Therapeutic time window and dose response of autologous bone marrow mononuclear cells for ischemic stroke. Journal of Neuroscience Research, 2011, 89, 833-839.	2.9	90
221	Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Annals of Neurology, 2011, 70, 59-69.	5.3	259
222	Zero on the NIHSS Does Not Equal the Absence of Stroke. Annals of Emergency Medicine, 2011, 57, 42-45.	0.6	111
223	Safety of High Doses of Urokinase and Reteplase for Acute Ischemic Stroke. American Journal of Neuroradiology, 2011, 32, 998-1001.	2.4	10
224	No Consensus on Definition Criteria for Stroke Registry Common Data Elements. Cerebrovascular Diseases Extra, $2011,1,84-92.$	<b>1.</b> 5	9
225	Pharmacological Deep Vein Thrombosis Prophylaxis Does Not Lead to Hematoma Expansion in Intracerebral Hemorrhage With Intraventricular Extension. Stroke, 2011, 42, 705-709.	2.0	36
226	Home Time Is Extended in Patients With Ischemic Stroke Who Receive Thrombolytic Therapy. Stroke, 2011, 42, 1046-1050.	2.0	36
227	Thrombolysis With Intravenous Tissue Plasminogen Activator Predicts a Favorable Discharge Disposition in Patients With Acute Ischemic Stroke. Stroke, 2011, 42, 700-704.	2.0	18
228	Cytoprotective Role of Haptoglobin in Brain After Experimental Intracerebral Hemorrhage. Acta Neurochirurgica Supplementum, 2011, 111, 107-112.	1.0	20
229	Necroptosis, a novel form of caspaseâ€independent cell death, contributes to neuronal damage in a retinal ischemiaâ€reperfusion injury model. Journal of Neuroscience Research, 2010, 88, 1569-1576.	2.9	209
230	Comment on US Geographic Distribution of Recombinant Tissue Plasminogen Activator Use by Hospitals for Acute Ischemic Stroke. Stroke, 2010, 41, e189; author reply e190.	2.0	1
231	Feasibility of carotid artery stenting in patients with angiographic string sign. Catheterization and Cardiovascular Interventions, 2010, 75, 1104-1109.	1.7	15
232	Bone marrow mononuclear cells protect neurons and modulate microglia in cell culture models of ischemic stroke. Journal of Neuroscience Research, 2010, 88, 2869-2876.	2.9	59
233	Autologous Bone Marrow Mononuclear Cells Enhance Recovery after Acute Ischemic Stroke in Young and Middle-Aged Rats. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 140-149.	4.3	190
234	The Spot Sign in Intracerebral Hemorrhage: The Importance of Looking for Contrast Extravasation. Cerebrovascular Diseases, 2010, 29, 217-220.	1.7	85

#	Article	lF	CITATIONS
235	Stroke treatment and prevention. Neurology, 2010, 75, S16-21.	1.1	8
236	Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke (ICTuS-L). Stroke, 2010, 41, 2265-2270.	2.0	324
237	Kids Identifying and Defeating Stroke (KIDS): Development and Implementation of a Multiethnic Health Education Intervention to Increase Stroke Awareness Among Middle School Students and Their Parents. Health Promotion Practice, 2010, 11, 95-103.	1.6	17
238	Caffeinol at the Receptor Level. Stroke, 2010, 41, 363-367.	2.0	15
239	Pattern of Response of National Institutes of Health Stroke Scale Components to Early Recanalization in the CLOTBUST Trial. Stroke, 2010, 41, 466-470.	2.0	11
240	Phase IIB/III Trial of Tenecteplase in Acute Ischemic Stroke. Stroke, 2010, 41, 707-711.	2.0	226
241	Intracerebral Hemorrhage in Cocaine Users. Stroke, 2010, 41, 680-684.	2.0	103
242	AXIS. Stroke, 2010, 41, 2545-2551.	2.0	116
243	Thrombolysis Is Associated With Consistent Functional Improvement Across Baseline Stroke Severity. Stroke, 2010, 41, 2612-2617.	2.0	79
244	Increased Blood–Brain Barrier Permeability on Perfusion CT Might Predict Malignant Middle Cerebral Artery Infarction. Stroke, 2010, 41, 2539-2544.	2.0	74
245	Introduction. Stroke, 2010, 41, S91.	2.0	3
246	Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet, The, 2010, 375, 1695-1703.	13.7	1,871
247	Thrombolytic Therapy for Patients Who Wake-Up With Stroke. Stroke, 2009, 40, 827-832.	2.0	139
248	Can Comprehensive Stroke Centers Erase the â€Weekend Effect'?. Cerebrovascular Diseases, 2009, 27, 107-113.	1.7	96
249	Recovery after Ischemic Stroke: Criteria for Good Outcome by Level of Disability at Day 7. Cerebrovascular Diseases, 2009, 28, 341-348.	1.7	21
250	Safety of Eptifibatide for Subcortical Stroke Progression. Cerebrovascular Diseases, 2009, 28, 595-600.	1.7	18
251	Is It Ethical to Have a Placebo Arm in Reperfusion Trials in the 3- to 6-Hour Time Window?. Stroke, 2009, 40, 1541-1542.	2.0	3
252	Identifying Patients at High Risk for Poor Outcome After Intra-Arterial Therapy for Acute Ischemic Stroke, 2009, 40, 1780-1785.	2.0	118

#	Article	IF	Citations
253	Preface. Stroke, 2009, 40, S1-S1.	2.0	1
254	Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window. Stroke, 2009, 40, 2433-2437.	2.0	105
255	Does Study Enrollment Delay Treatment With Intravenous Thrombolytics for Acute Ischemic Stroke?. Stroke, 2009, 40, 663-663.	2.0	3
256	Intravenous Tissue Plasminogen Activator in Patients With Cocaine-Associated Acute Ischemic Stroke. Stroke, 2009, 40, 3635-3637.	2.0	32
257	Stroke Outcome in Clinical Trial Patients Deriving From Different Countries. Stroke, 2009, 40, 35-40.	2.0	37
258	Neuronal PPAR $\hat{I}^3$ Deficiency Increases Susceptibility to Brain Damage after Cerebral Ischemia. Journal of Neuroscience, 2009, 29, 6186-6195.	3.6	148
259	Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial. Annals of Neurology, 2009, 66, 28-38.	5.3	220
260	Mutations in Smooth Muscle Alpha-Actin (ACTA2) Cause Coronary Artery Disease, Stroke, and Moyamoya Disease, Along with Thoracic Aortic Disease. American Journal of Human Genetics, 2009, 84, 617-627.	6.2	466
261	Combined Neuroprotective Modalities Coupled with Thrombolysis in Acute Ischemic Stroke: A Pilot Study of Caffeinol and Mild Hypothermia. Journal of Stroke and Cerebrovascular Diseases, 2009, 18, 86-96.	1.6	72
262	Neuroprotective Role of Haptoglobin after Intracerebral Hemorrhage. Journal of Neuroscience, 2009, 29, 15819-15827.	3.6	136
263	Bone marrow-derived mononuclear cell populations in pediatric and adult patients. Cytotherapy, 2009, 11, 480-484.	0.7	7
264	The IVH Score: A novel tool for estimating intraventricular hemorrhage volume: Clinical and research implications*. Critical Care Medicine, 2009, 37, 969-e1.	0.9	118
265	Response to Letters by Furlan, and Kohrmann and Schwab. Stroke, 2009, 40, .	2.0	3
266	LOAD: A Pilot Study of the Safety of Loading of Aspirin and Clopidogrel in Acute Ischemic Stroke and Transient Ischemic Attack. Journal of Stroke and Cerebrovascular Diseases, 2008, 17, 26-29.	1.6	44
267	A Pilot Randomized Clinical Safety Study of Sonothrombolysis Augmentation With Ultrasound-Activated Perflutren-Lipid Microspheres for Acute Ischemic Stroke. Stroke, 2008, 39, 1464-1469.	2.0	158
268	Antiplatelet Therapy and the Risk of Intracranial Hemorrhage After Intravenous Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke. Archives of Neurology, 2008, 65, 575-6.	4.5	8
269	The Complications of Cardioembolic Stroke: Lessons from the VISTA Database. Cerebrovascular Diseases, 2008, 26, 38-40.	1.7	9
270	Thrombus Burden Is Associated With Clinical Outcome After Intra-Arterial Therapy for Acute Ischemic Stroke, 2008, 39, 3231-3235.	2.0	79

#	Article	IF	Citations
271	Anticoagulation After Cardioembolic Stroke. Archives of Neurology, 2008, 65, 1169.	4.5	58
272	The Argatroban and tPA Stroke Study. Progress in Neurotherapeutics and Neuropsychopharmacology, 2008, 3, .	0.0	1
273	Aggressive Blood Pressure–Lowering Treatment Before Intravenous Tissue Plasminogen Activator Therapy in Acute Ischemic Stroke. Archives of Neurology, 2008, 65, 1174-8.	4.5	46
274	The Effect of Activated Factor VII for Intracerebral Hemorrhage Beyond 3 Hours Versus Within 3 Hours. Stroke, 2008, 39, 473-475.	2.0	9
275	Stroke Program Review Group. Stroke, 2008, 39, 1364-1370.	2.0	35
276	A Randomized, Controlled Trial to Teach Middle School Children to Recognize Stroke and Call 911. Stroke, 2007, 38, 2972-2978.	2.0	101
277	Accuracy of Serial National Institutes of Health Stroke Scale Scores to Identify Artery Status in Acute Ischemic Stroke. Circulation, 2007, 115, 2660-2665.	1.6	36
278	Is Intra-Arterial Thrombolysis Safe After Full-Dose Intravenous Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke?. Stroke, 2007, 38, 80-84.	2.0	103
279	The Virtual International Stroke Trials Archive. Stroke, 2007, 38, 1905-1910.	2.0	101
280	Transcription Factor Nrf2 Protects the Brain From Damage Produced by Intracerebral Hemorrhage. Stroke, 2007, 38, 3280-3286.	2.0	202
281	Safety and Tolerability of NXY-059 for Acute Intracerebral Hemorrhage. Stroke, 2007, 38, 2262-2269.	2.0	162
282	Constraint-Induced Movement Therapy During Early Stroke Rehabilitation. Neurorehabilitation and Neural Repair, 2007, 21, 14-24.	2.9	167
283	Intravenous rt-PA: a tenth anniversary reflection. World Neurosurgery, 2007, 68, S12-S16.	1.3	18
284	Established treatments for acute ischaemic stroke. Lancet, The, 2007, 369, 319-330.	13.7	94
285	Acute Posterior Multifocal Placoid Pigment Epitheliopathy After Cerebral Sinus Thrombosis. Neuro-Ophthalmology, 2007, 31, 117-120.	1.0	0
286	NXY-059 for the Treatment of Acute Ischemic Stroke. New England Journal of Medicine, 2007, 357, 562-571.	27.0	664
287	Hematoma resolution as a target for intracerebral hemorrhage treatment: Role for peroxisome proliferatorâ€activated receptor γ in microglia/macrophages. Annals of Neurology, 2007, 61, 352-362.	5.3	319
288	SITS-MOST: old myths laid to rest. Lancet Neurology, The, 2007, 6, 292-293.	10.2	2

#	Article	lF	Citations
289	Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics. Neurocritical Care, 2007, 6, 181-185.	2.4	14
290	Kids Identifying and Defeating Stroke (KIDS): design of a school-based intervention to improve stroke awareness. Ethnicity and Disease, 2007, 17, 320-6.	2.3	5
291	Alteplase for acute ischemic stroke. Expert Review of Cardiovascular Therapy, 2006, 4, 301-318.	1.5	6
292	Safety and tolerability of arundic acid in acute ischemic stroke. Journal of the Neurological Sciences, 2006, 251, 50-56.	0.6	35
293	Argatroban tPA Stroke Study. Archives of Neurology, 2006, 63, 1057.	4.5	72
294	Telemedicine-Guided Carotid and Transcranial Ultrasound. Stroke, 2006, 37, 229-230.	2.0	25
295	Using Telemedicine to Facilitate Thrombolytic Therapy for Patients with Acute Stroke. Joint Commission Journal on Quality and Patient Safety, 2006, 32, 199-205.	0.7	34
296	Distinct patterns of intracerebral hemorrhage-induced alterations in NF-κB subunit, iNOS, and COX-2 expression. Journal of Neurochemistry, 2006, 101, 652-663.	3.9	113
297	Intracerebral Hemorrhage: Effective Therapy at Last?. International Journal of Stroke, 2006, 1, 30-31.	5.9	1
298	15d-Prostaglandin J <sub>2</sub> Activates Peroxisome Proliferator-Activated Receptor-γ, Promotes Expression of Catalase, and Reduces Inflammation, Behavioral Dysfunction, and Neuronal Loss after Intracerebral Hemorrhage in Rats. Journal of Cerebral Blood Flow and Metabolism, 2006, 26, 811-820.	4.3	222
299	Latest advances in intracerebral hemorrhage. Current Neurology and Neuroscience Reports, 2006, 6, 17-22.	4.2	42
300	Peroxisome-proliferator-activated receptor-gamma (PPAR $\hat{I}^3$ ) activation protects neurons from NMDA excitotoxicity. Brain Research, 2006, 1073-1074, 460-469.	2.2	80
301	Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPARγ) and 15d-prostaglandin J2—Mediated protection of brain after experimental cerebral ischemia in rat. Brain Research, 2006, 1096, 196-203.	2.2	74
302	Additional Outcomes and Subgroup Analyses of NXY-059 for Acute Ischemic Stroke in the SAINT I Trial. Stroke, 2006, 37, 2970-2978.	2.0	51
303	Does Clinical-CT â€~Mismatch' Predict Early Response to Treatment with Recombinant Tissue Plasminogen Activator?. Cerebrovascular Diseases, 2006, 22, 384-388.	1.7	10
304	Functional Reorganization and Recovery After Constraint-Induced Movement Therapy in Subacute Stroke: Case Reports. Neurocase, 2006, 12, 50-60.	0.6	64
305	NXY-059 for Acute Ischemic Stroke. New England Journal of Medicine, 2006, 354, 588-600.	27.0	632
306	Yield and Accuracy of Urgent Combined Carotid/Transcranial Ultrasound Testing in Acute Cerebral Ischemia. Stroke, 2005, 36, 32-37.	2.0	135

#	Article	IF	CITATIONS
307	Beyond subgroup analysis: improving the clinical interpretation of treatment effects in stroke research. Journal of Neuroscience Methods, 2005, 143, 209-216.	2.5	34
308	The Impact of Imbalances in Baseline Stroke Severity on Outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. Annals of Emergency Medicine, 2005, 45, 377-384.	0.6	46
309	New era for management of primary hypertensive intracerebral hemorrhage. Current Neurology and Neuroscience Reports, 2005, 5, 29-35.	4.2	5
310	Wheel-Running Modestly Promotes Functional Recovery after a Unilateral Cortical Lesion in Rats. Behavioural Neurology, 2005, 16, 41-49.	2.1	15
311	Houston Paramedic and Emergency Stroke Treatment and Outcomes Study (HoPSTO). Stroke, 2005, 36, 1512-1518.	2.0	203
312	Safety and Feasibility of a Lower Dose Intravenous TPA Therapy for Ischemic Stroke beyond the First Three Hours. Cerebrovascular Diseases, 2005, 19, 260-266.	1.7	13
313	Combining Insulin-Like Growth Factor Derivatives Plus Caffeinol Produces Robust Neuroprotection After Stroke in Rats. Stroke, 2005, 36, 129-134.	2.0	33
314	Aggressive Mechanical Clot Disruption. Stroke, 2005, 36, 292-296.	2.0	172
315	NIHSS Training and Certification Using a New Digital Video Disk Is Reliable. Stroke, 2005, 36, 2446-2449.	2.0	118
316	Asymptomatic hemorrhagic transformation of cerebral infarction does not worsen long-term outcome. Journal of Stroke and Cerebrovascular Diseases, 2005, 14, 50-54.	1.6	22
317	Intravenous TPA for Very Old Stroke Patients. European Neurology, 2005, 54, 140-144.	1.4	58
318	Endovascular recanalization of internal carotid artery occlusion in acute ischemic stroke. American Journal of Neuroradiology, 2005, 26, 2591-4.	2.4	33
319	Ultrasound-Enhanced Systemic Thrombolysis for Acute Ischemic Stroke. New England Journal of Medicine, 2004, 351, 2170-2178.	27.0	1,006
320	Increased Pelvic Vein Thrombi in Cryptogenic Stroke. Stroke, 2004, 35, 46-50.	2.0	215
321	Ischemic Stunning of the Brain. Stroke, 2004, 35, 449-452.	2.0	121
322	CLOTBUST: Design of a Randomized Trial of Ultrasoundâ€Enhanced Thrombolysis for Acute Ischemic Stroke. Journal of Neuroimaging, 2004, 14, 108-112.	2.0	89
323	Ultrasoundâ€Enhanced Thrombolysis for Acute Ischemic Stroke: Phase I. Findings of the CLOTBUST Trial. Journal of Neuroimaging, 2004, 14, 113-117.	2.0	125
324	Treatment of Acute Intracerebral Hemorrhage with $\hat{l}\mu\text{-Aminocaproic Acid: A Pilot Study.}$ Neurocritical Care, 2004, 1, 47-52.	2.4	57

#	Article	IF	Citations
325	Management of primary hypertensive hemorrhage of the brain. Current Treatment Options in Neurology, 2004, 6, 435-442.	1.8	6
326	A prospective, multicenter pilot study to evaluate the feasibility and safety of using the CoolGardâ,,¢ System and Icyâ,,¢ catheter following cardiac arrest. Resuscitation, 2004, 62, 143-150.	3.0	228
327	Constraint-Induced Movement Therapy. Stroke, 2004, 35, 2699-2701.	2.0	105
328	Clinical trials for cytoprotection in stroke. NeuroRx, 2004, 1, 46-70.	6.0	110
329	Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet, The, 2004, 363, 768-774.	13.7	2,316
330	Chapter 13 Thrombolytic Therapies. Blue Books of Practical Neurology, 2004, 29, 267-281.	0.1	1
331	Pharmacologic Modification of Acute Cerebral Ischemia. , 2004, , 1025-1058.		3
332	Ultrasound-Enhanced Thrombolysis for Acute Ischemic Stroke: Phase I. Findings of the CLOTBUST Trial. , 2004, 14, 113-117.		55
333	Clinical trials for cytoprotection in stroke. Neurotherapeutics, 2004, 1, 46-70.	4.4	0
334	CLOTBUST: design of a randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke., 2004, 14, 108-12.		22
335	Ultrasound-enhanced thrombolysis for acute ischemic stroke: phase I. Findings of the CLOTBUST trial. , 2004, 14, 113-7.		46
336	Paradoxical Emboli from Calf and Pelvic Veins in Cryptogenic Stroke. Journal of Neuroimaging, 2003, 13, 218-223.	2.0	23
337	Adding to the Effectiveness of Intravenous Tissue Plasminogen Activator for Treating Acute Stroke. Circulation, 2003, 107, 2769-2770.	1.6	8
338	Is the Benefit of Early Recanalization Sustained at 3 Months?. Stroke, 2003, 34, 695-698.	2.0	113
339	Pilot Dose-Escalation Study of Caffeine Plus Ethanol (Caffeinol) in Acute Ischemic Stroke. Stroke, 2003, 34, 1242-1245.	2.0	64
340	Ethanol Plus Caffeine (Caffeinol) for Treatment of Ischemic Stroke. Stroke, 2003, 34, 1246-1251.	2.0	106
341	NIHSS/EIC Mismatch Explains the > 1/3 MCA Conundrum. Stroke, 2003, 34, e148-9; author reply e148-9.	2.0	7
342	Sustained Benefit of a Community and Professional Intervention to Increase Acute Stroke Therapy. Archives of Internal Medicine, 2003, 163, 2198.	3.8	110

#	Article	IF	CITATIONS
343	Paramedic and Emergency Department Care of Stroke: Baseline Data From a Citywide Performance Improvement Study. American Journal of Critical Care, 2003, 12, 411-417.	1.6	36
344	Paramedic and emergency department care of stroke: baseline data from a citywide performance improvement study. American Journal of Critical Care, 2003, 12, 411-7.	1.6	13
345	Acetaminophen for Altering Body Temperature in Acute Stroke. Stroke, 2002, 33, 130-135.	2.0	180
346	Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology, 2002, 59, 862-867.	1.1	429
347	Improving Delivery of Acute Stroke Therapy. Stroke, 2002, 33, 160-166.	2.0	232
348	Early Dramatic Recovery During Intravenous Tissue Plasminogen Activator Infusion. Stroke, 2002, 33, 1301-1307.	2.0	136
349	The NINDS stroke study group response. Journal of Stroke and Cerebrovascular Diseases, 2002, 11, 121-124.	1.6	9
350	Neuroprotection Is Unlikely to Be Effective in Humans Using Current Trial Designs. Stroke, 2002, 33, 306-307.	2.0	103
351	Safety of Tissue Plasminogen Activator for Acute Stroke in Menstruating Women. Stroke, 2002, 33, 2506-2508.	2.0	29
352	Neuroprotection after cardiac arrest. Lancet Neurology, The, 2002, 1, 146.	10.2	4
352 353		10.2	183
	Neuroprotection after cardiac arrest. Lancet Neurology, The, 2002, 1, 146.  Cell death in experimental intracerebral hemorrhage: The "black hole―model of hemorrhagic damage.		
353	Neuroprotection after cardiac arrest. Lancet Neurology, The, 2002, 1, 146.  Cell death in experimental intracerebral hemorrhage: The "black hole―model of hemorrhagic damage. Annals of Neurology, 2002, 51, 517-524.  Intravenous Tissue Plasminogen Activator and Flow Improvement in Acute Ischemic Stroke Patients	5.3	183
353 354	Neuroprotection after cardiac arrest. Lancet Neurology, The, 2002, 1, 146.  Cell death in experimental intracerebral hemorrhage: The "black hole―model of hemorrhagic damage. Annals of Neurology, 2002, 51, 517-524.  Intravenous Tissue Plasminogen Activator and Flow Improvement in Acute Ischemic Stroke Patients with Internal Carotid Artery Occlusion. Journal of Neuroimaging, 2002, 12, 119-123.  Intracranial balloon angioplasty of acute terminal internal carotid artery occlusions. American	5.3	183 150
353 354 355	Neuroprotection after cardiac arrest. Lancet Neurology, The, 2002, 1, 146.  Cell death in experimental intracerebral hemorrhage: The "black hole―model of hemorrhagic damage. Annals of Neurology, 2002, 51, 517-524.  Intravenous Tissue Plasminogen Activator and Flow Improvement in Acute Ischemic Stroke Patients with Internal Carotid Artery Occlusion. Journal of Neuroimaging, 2002, 12, 119-123.  Intracranial balloon angioplasty of acute terminal internal carotid artery occlusions. American Journal of Neuroradiology, 2002, 23, 1308-12.  Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke, 2002, 33,	5.3 2.0 2.4	183 150 20
353 354 355 356	Neuroprotection after cardiac arrest. Lancet Neurology, The, 2002, 1, 146.  Cell death in experimental intracerebral hemorrhage: The "black hole―model of hemorrhagic damage. Annals of Neurology, 2002, 51, 517-524.  Intravenous Tissue Plasminogen Activator and Flow Improvement in Acute Ischemic Stroke Patients with Internal Carotid Artery Occlusion. Journal of Neuroimaging, 2002, 12, 119-123.  Intracranial balloon angioplasty of acute terminal internal carotid artery occlusions. American Journal of Neuroradiology, 2002, 23, 1308-12.  Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke, 2002, 33, 306-7.  Combination Therapy Stroke Trial: Recombinant Tissue-Type Plasminogen Activator with/without	5.3 2.0 2.4 2.0	183 150 20 28
353 354 355 356	Neuroprotection after cardiac arrest. Lancet Neurology, The, 2002, 1, 146.  Cell death in experimental intracerebral hemorrhage: The "black hole―model of hemorrhagic damage. Annals of Neurology, 2002, 51, 517-524.  Intravenous Tissue Plasminogen Activator and Flow Improvement in Acute Ischemic Stroke Patients with Internal Carotid Artery Occlusion. Journal of Neuroimaging, 2002, 12, 119-123.  Intracranial balloon angioplasty of acute terminal internal carotid artery occlusions. American Journal of Neuroradiology, 2002, 23, 1308-12.  Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke, 2002, 33, 306-7.  Combination Therapy Stroke Trial: Recombinant Tissue-Type Plasminogen Activator with/without Lubeluzole. Cerebrovascular Diseases, 2001, 12, 258-263.	5.3 2.0 2.4 2.0	183 150 20 28

#	Article	IF	CITATIONS
361	Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. Annals of Neurology, 2001, 49, 736-744.	5.3	54
362	A Broad Diagnostic Battery for Bedside Transcranial Doppler to Detect Flow Changes With Internal Carotid Artery Stenosis or Occlusion. Journal of Neuroimaging, 2001, 11, 236-242.	2.0	77
363	Intravenous Tissue-Type Plasminogen Activator Therapy for Ischemic Stroke. Archives of Neurology, 2001, 58, 2009.	4.5	216
364	Preventing Stroke. Circulation, 2001, 103, 2321-2322.	1.6	10
365	Speed of Intracranial Clot Lysis With Intravenous Tissue Plasminogen Activator Therapy. Circulation, 2001, 103, 2897-2902.	1.6	274
366	Dramatic Recovery During IV-TPA Infusion: Time Course and Clinical Pattern. Stroke, 2001, 32, 370-370.	2.0	0
367	Intravenous TPA for Ischemic Stroke Patients: Houston Experience 1996–2000. Stroke, 2001, 32, 323-323.	2.0	14
368	Neuroprotection and the Ischemic Cascade. CNS Spectrums, 2000, 5, 52-58.	1.2	43
369	Accuracy and Criteria for Localizing Arterial Occlusion With Transcranial Doppler. Journal of Neuroimaging, 2000, 10, 1-12.	2.0	179
370	Specific Transcranial Doppler Flow Findings Related to the Presence and Site of Arterial Occlusion. Stroke, 2000, 31, 140-146.	2.0	159
371	Early Exclusive Use of the Affected Forelimb After Moderate Transient Focal Ischemia in Rats. Stroke, 2000, 31, 1144-1152.	2.0	172
372	Finding the Most Powerful Measures of the Effectiveness of Tissue Plasminogen Activator in the NINDS tPA Stroke Trial. Stroke, 2000, 31, 2335-2341.	2.0	138
373	High Rate of Complete Recanalization and Dramatic Clinical Recovery During tPA Infusion When Continuously Monitored With 2-MHz Transcranial Doppler Monitoring. Stroke, 2000, 31, 610-614.	2.0	338
374	Timing of Recanalization After Tissue Plasminogen Activator Therapy Determined by Transcranial Doppler Correlates With Clinical Recovery From Ischemic Stroke. Stroke, 2000, 31, 1812-1816.	2.0	241
375	Deterioration Following Spontaneous Improvement. Stroke, 2000, 31, 915-919.	2.0	121
376	Activation of Emergency Medical Services for Acute Stroke in a Nonurban Population. Stroke, 2000, 31, 1925-1928.	2.0	129
377	Interplay Between the Gamma Isoform of PKC and Calcineurin in Regulation of Vulnerability to Focal Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 343-349.	4.3	50
378	Transcranial Doppler Ultrasound Criteria for Recanalization After Thrombolysis for Middle Cerebral Artery Stroke. Stroke, 2000, 31, 1128-1132.	2.0	226

#	Article	IF	CITATIONS
379	Yield of Transcranial Doppler in Acute Cerebral Ischemia. Stroke, 1999, 30, 1604-1609.	2.0	185
380	Nuclear Factor-κB and Cell Death After Experimental Intracerebral Hemorrhage in Rats. Stroke, 1999, 30, 2472-2478.	2.0	166
381	Neurofilament Proteolysis after Focal Ischemia; When Do Cells Die after Experimental Stroke?. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 652-660.	4.3	47
382	What is the Role of Stroke Units in Overall Care?. Disease Management and Health Outcomes, 1999, 6, 193-202.	0.4	3
383	Ischemic stroke pathophysiology. Journal of Stroke and Cerebrovascular Diseases, 1999, 8, 114-116.	1.6	5
384	Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke, 1999, 30, 905-915.	2.0	778
385	Combined Intravenous and Intra-Arterial r-TPA Versus Intra-Arterial Therapy of Acute Ischemic Stroke. Stroke, 1999, 30, 2598-2605.	2.0	636
386	Serum Glucose Level and Diabetes Predict Tissue Plasminogen Activator–Related Intracerebral Hemorrhage in Acute Ischemic Stroke. Stroke, 1999, 30, 34-39.	2.0	355
387	Agreement and Variability in the Interpretation of Early CT Changes in Stroke Patients Qualifying for Intravenous rtPA Therapy. Stroke, 1999, 30, 1528-1533.	2.0	285
388	Acute Stroke Therapy at the Millennium: Consummating the Marriage Between the Laboratory and Bedside. Stroke, 1999, 30, 1722-1728.	2.0	51
389	Does the National Institutes of Health Stroke Scale Favor Left Hemisphere Strokes?. Stroke, 1999, 30, 2355-2359.	2.0	173
390	Discussion of mitchell JB, Ballard DJ, whisnant JP, et al. What role do neurologists play in determining the costs and outcome of stroke patients? stroke 1996;27:1937–1943. Journal of Stroke and Cerebrovascular Diseases, 1998, 7, 267-271.	1.6	0
391	Urokinase treatment of sagittal sinus thrombosis with venous hemorrhagic infarction. Journal of Stroke and Cerebrovascular Diseases, 1998, 7, 421-425.	1.6	21
392	ISCHEMIC STROKE. Neurologic Clinics, 1998, 16, 355-372.	1.8	11
393	Neuroprotective Therapy. Seminars in Neurology, 1998, 18, 485-492.	1.4	105
394	Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke. Stroke, 1998, 29, 18-22.	2.0	349
395	tPA-Associated Reperfusion After Acute Stroke Demonstrated by SPECT. Stroke, 1998, 29, 429-432.	2.0	113
396	Hypertension and Its Treatment in the NINDS rt-PA Stroke Trial. Stroke, 1998, 29, 1504-1509.	2.0	209

#	Article	IF	CITATIONS
397	Clinical Features of Moyamoya Disease in the United States. Stroke, 1998, 29, 1347-1351.	2.0	295
398	Emergency Identification and Treatment of Acute Ischemic Stroke. Annals of Emergency Medicine, 1997, 30, 642-653.	0.6	25
399	Reperfusion Injury: Demonstration of Brain Damage Produced by Reperfusion after Transient Focal Ischemia in Rats. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 1048-1056.	4.3	342
400	Elective Stenting of Extracranial Carotid Arteries. Circulation, 1997, 95, 303-305.	1.6	32
401	African Americans and Women Have the Highest Stroke Mortality in Texas. Stroke, 1997, 28, 15-18.	2.0	26
402	Lubeluzole Treatment of Acute Ischemic Stroke. Stroke, 1997, 28, 2338-2346.	2.0	144
403	Grading Carotid Stenosis With Ultrasound. Stroke, 1997, 28, 1208-1210.	2.0	60
404	Brain Single-Photon Emission CT With HMPAO and Safety of Thrombolytic Therapy in Acute Ischemic Stroke, 1997, 28, 1830-1834.	2.0	48
405	Demonstration of hypoperfusion surrounding intracerebral hematoma in humans. Journal of Stroke and Cerebrovascular Diseases, 1996, 6, 17-24.	1.6	46
406	Citicoline for treatment of experimental focal ischemia: Histologic and behavioral outcome. Neurological Research, 1996, 18, 570-574.	1.3	63
407	Ca2+/calmodulin-dependent protein kinase II in postsynaptic densities after reversible cerebral ischemia in rats. Brain Research, 1996, 709, 103-110.	2.2	26
408	Cerebral Venous Thrombosis — A New Diagnosis in Travel Medicine. Journal of Travel Medicine, 1996, 3, 137-137.	3.0	14
409	Ischemia-Induced Neuronal Damage: A Role for Calcium/Calmodulin-Dependent Protein Kinase II. Journal of Cerebral Blood Flow and Metabolism, 1996, 16, 1-6.	4.3	97
410	An Alternative Method for the Quantitation of Neuronal Damage after Experimental Middle Cerebral Artery Occlusion in Rats: Analysis of Behavioral Deficit. Journal of Cerebral Blood Flow and Metabolism, 1996, 16, 705-713.	4.3	93
411	Rodent Models of Stroke Limitations. Archives of Neurology, 1996, 53, 1067.	4.5	13
412	Guidelines for Thrombolytic Therapy for Acute Stroke: A Supplement to the Guidelines for the Management of Patients With Acute Ischemic Stroke. Circulation, 1996, 94, 1167-1174.	1.6	429
413	Safety and Tolerability of the Glutamate Antagonist CGS 19755 (Selfotel) in Patients With Acute Ischemic Stroke. Stroke, 1995, 26, 602-605.	2.0	172
414	Subjective Experiences of 24 Patients Dramatically Recovering From Stroke. Stroke, 1995, 26, 1285-1288.	2.0	33

#	Article	IF	CITATIONS
415	The Current Status of Neuronal Protective Therapy: Why Have All Neuronal Protective Drugs Worked in Animals but None So Far in Stroke Patients?. Cerebrovascular Diseases, 1994, 4, 115-120.	1.7	61
416	Neuronal Protection and Preservation of Calcium/Calmodulin-Dependent Protein Kinase II and Protein Kinase C Activity by Dextrorphan Treatment in Global Ischemia. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 550-557.	4.3	31
417	New Uses for Calcium Channel Blockers. Drugs, 1993, 46, 961-975.	10.9	48
418	Ischemia-Induced Translocation of Ca2+/Calmodulin-Dependent Protein Kinase II: Potential Role in Neuronal Damage. Journal of Neurochemistry, 1992, 58, 1743-1753.	3.9	134
419	Clinical Aspects of the Use of Calcium Antagonists in Cerebrovascular Disease. Clinical Neuropharmacology, 1991, 14, 373-390.	0.7	29
420	Immunohistochemical Determination of Calciumâ€"Calmodulin Binding Predicts Neuronal Damage after Global Ischemia. Journal of Cerebral Blood Flow and Metabolism, 1989, 9, 805-811.	4.3	52
421	Sj $\tilde{A}$ ¶gren's syndrome and other rheumatic disorders presenting to a neurology service. Journal of Autoimmunity, 1989, 2, 477-483.	6.5	7
422	Current Medical and Surgical Therapy for Cerebrovascular Disease. New England Journal of Medicine, 1987, 317, 1505-1516.	27.0	108
423	Metastatic renal cell carcinoma simulating glumus jugulare tumor. Journal of Surgical Oncology, 1987, 35, 201-203.	1.7	11
424	Brain extraction of a calcium channel blocker. Annals of Neurology, 1987, 21, 171-175.	5.3	36
425	Oculomasticatory myorhythmia. Annals of Neurology, 1987, 22, 395-396.	5.3	24
426	Emerging Stroke Therapies. Seminars in Neurology, 1986, 6, 285-292.	1.4	8
427	Asymptomatic Carotid Bruit and Stenosis. Seminars in Neurology, 1986, 6, 262-266.	1.4	5
428	Carotici Artery Disease Following ExternalCervical Irradiation. Annals of Surgery, 1981, 194, 609-615.	4.2	151
429	The Argatroban and tPA Stroke Study. , 0, , 35-48.		3
430	The Spot Sign and Intraventricular Hemorrhage are Associated with Baseline Coagulopathy and Outcome in Intracerebral Hemorrhage. Neurocritical Care, 0, , .	2.4	1